Literature DB >> 20206542

Trans-apical aortic valve implantation: univariate and multivariate analyses of the early results from the SOURCE registry.

Olaf Wendler1, Thomas Walther, Patrick Nataf, Paolo Rubino, Holger Schroefel, Matthias Thielmann, Hendrik Treede, Martyn Thomas.   

Abstract

OBJECTIVE: Trans-catheter aortic valve implantation is an alternative treatment option for patients facing high risk for aortic valve replacement. Currently, the results of trans-apical trans-catheter procedures performed outside controlled trials are unknown.
METHODS: The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry collects data of patients treated at European centres during the first year following commercialisation of the Edwards SAPIEN bioprosthesis. Only data from centres that could provide 100% of their consecutively treated patients (n=32) were included in the study population. This article provides the 30-day outcome data involving the trans-apical patients, including univariate and multivariate risk analyses for postoperative 30-day mortality.
RESULTS: The interim results are based on a total number of 575 procedures performed between January 2008 and 31 January 2009. Mean age at implant was 80.7 years, and patients had a mean logistic EuroSCORE of 29.1%. Baseline characteristics included coronary artery disease 56%, prior coronary intervention 27.1%, prior coronary bypass grafting 26.9%, concomitant mitral valve disease 32.8%, porcelain aorta 11.5%, peripheral vascular disease 27.5%, prior stroke 6.3% and pulmonary disease 29.4%. Successful valve deployment was observed in 92.7% with a 3.5% conversion rate to open surgery, incidence of coronary obstruction of 0.7% and valve embolisation of 0.5%. The incidence of aortic regurgitation in excess of 2+ was 2.3% immediately following the procedure. The incidence of major postoperative complications included bleeding requiring re-operation 2.1%, dialysis 7.1%, pacemaker implantation 7.3%, stroke 2.6%, major vascular complications 2.4% and myocardial infarction 0.7%. The total 30-day mortality was 10.3%. Logistic EuroSCORE > or =30% and missing ejection fraction were found to be the only independent predictors for 30-day mortality.
CONCLUSIONS: These results demonstrate that although trans-apical trans-catheter aortic valve implantation is a complex surgical technique, the learning curve can be minimised by appropriate training programmes. Very high logistic EuroSCOREs predict inferior survival and make it likely that in this subgroup of patients there may be some who, despite having had a successful trans-catheter aortic valve implantation procedure, do not benefit in the midterm. Crown Copyright 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20206542     DOI: 10.1016/j.ejcts.2009.12.048

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  12 in total

Review 1.  Current developments in transcatheter aortic valve implantation techniques.

Authors:  M Thielmann; P Kahlert; T Konorza; R Erbel; H Jakob; D Wendt
Journal:  Herz       Date:  2011-12       Impact factor: 1.443

2.  Emerging approaches of transcatheter valve repair/insertion.

Authors:  Maurizio Taramasso; Micaela Cioni; Andrea Giacomini; Iassen Michev; Cosmo Godino; Matteo Montorfano; Antonio Colombo; Ottavio Alfieri; Francesco Maisano
Journal:  Cardiol Res Pract       Date:  2010-07-25       Impact factor: 1.866

3.  One year follow-up of the multi-centre European PARTNER transcatheter heart valve study.

Authors:  Thierry Lefèvre; Ari Pieter Kappetein; Ernst Wolner; Patrick Nataf; Martyn Thomas; Volker Schächinger; Bernard De Bruyne; Hélène Eltchaninoff; Matthias Thielmann; Dominique Himbert; Mauro Romano; Patrick Serruys; Gerhard Wimmer-Greinecker
Journal:  Eur Heart J       Date:  2010-11-12       Impact factor: 29.983

4.  Transapical aortic valve implantation - The Leipzig experience.

Authors:  David M Holzhey; Martin Hänsig; Thomas Walther; Joerg Seeburger; Martin Misfeld; Axel Linke; Michael A Borger; Friedrich W Mohr
Journal:  Ann Cardiothorac Surg       Date:  2012-07

Review 5.  Restrictive and liberal red cell transfusion strategies in adult patients: reconciling clinical data with best practice.

Authors:  Marek A Mirski; Steven M Frank; Daryl J Kor; Jean-Louis Vincent; David R Holmes
Journal:  Crit Care       Date:  2015-05-05       Impact factor: 9.097

6.  Recent advances in transcatheter aortic valve implantation: novel devices and potential shortcomings.

Authors:  J Blumenstein; C Liebetrau; A Van Linden; H Moellmann; T Walther; J Kempfert
Journal:  Curr Cardiol Rev       Date:  2013-11

7.  Transaortic transcatheter aortic valve implantation - rationale and design of the multicenter, multinational prospective ROUTE registry.

Authors:  Peter Bramlage; Mauro Romano; Nikolaos Bonaros; Ricardo Cocchieri; Dariusz Jagielak; Derk Frank; Vinayak Bapat
Journal:  BMC Cardiovasc Disord       Date:  2014-11-01       Impact factor: 2.298

8.  Successful trans-apical aortic valve implantation for a high risk patient with aortic stenosis using a new second-generation TAVI device - J-Valve system.

Authors:  Jiahan Cheng; Miao Chen; Da Zhu; Ji Zhang; Jia Hu; Yingqiang Guo
Journal:  J Cardiothorac Surg       Date:  2015-01-17       Impact factor: 1.637

9.  Transapical transcatheter aortic valve replacement in patients with or without prior coronary artery bypass graft operation.

Authors:  Konstantinos V Voudris; S Chiu Wong; Ryan Kaple; Polydoros N Kampaktsis; Andreas R de Biasi; Jonathan S Weiss; Richard Devereux; Karl Krieger; Luke Kim; Rajesh V Swaminathan; Dmitriy N Feldman; Harsimran Singh; Nikolaos J Skubas; Robert M Minutello; Geoffrey Bergman; Arash Salemi
Journal:  J Cardiothorac Surg       Date:  2016-11-29       Impact factor: 1.637

10.  Mid-term results of 150 TAVI comparing apical versus femoral approaches.

Authors:  Alain Rougé; Olivier Huttin; Rumas Aslam; Thibaud Vaugrenard; Thomas Jouve; Michael Angioi; Pablo Maureira
Journal:  J Cardiothorac Surg       Date:  2015-11-03       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.